All In Biotech

Drug Trial Radar · NCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

548

Actual

Start

Dec 21, 2020

Primary completion

Nov 13, 2026

Study completion Mar 5, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)

Conditions

  • Advanced Solid Tumors

Interventions

  • REGN7075Drug

    Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)

  • CemiplimabDrug

    Administered concomitantly Q3W by IV infusion or SC injection

  • Platinum-based doublet chemotherapyDrug

    Administered IV Q3W

  • BevacizumabDrug

    Administered per protocol

  • Trifluridine-tipiracilDrug

    Administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Dose-Limiting Toxicities (DLTs) during the DLT periodTime frame: Up to 6 weeks
  2. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 90 days from last dose; up to 5 years
  3. Incidence and severity of Adverse Events of Special Interest (AESIs)Time frame: Approximately 90 days from last dose; up to 5 years
  4. Incidence and severity of Serious Adverse Events (SAEs)Time frame: Approximately 90 days from last dose; up to 5 years
  5. Incidence and severity of grade ≥3 laboratory abnormalitiesTime frame: Approximately 90 days from last dose; up to 5 years
  6. Objective Response Rate (ORR)Time frame: Up to 5 years

Locations

54 sites in 7 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • University of California Los Angeles (UCLA) Medical Center

    Los Angeles, California

  • The Regents of the University of California, San Francisco

    San Francisco, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic

    Aurora, Colorado

  • University of Florida Health

    Gainesville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Illinois Cancer Center

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • START Midwest - Cancer & Hematology Centers of Western Michigan, PC

    Grand Rapids, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • The Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute - 25th Ave

    Nashville, Tennessee

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • South Texas Oncology And Hematology

    San Antonio, Texas

  • University of Washington/Fred Hutchinson Cancer Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Hospital Paris Saint-Joseph

    Paris, France

  • Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL)

    Lyon, Auvergne-Rhone, France

  • Hopital Lyon Sud

    Pierre-Bénite, Auvergne-Rhône, France

  • Centre Georges Francois Leclerc

    Dijon, Bourgogne-Franche-Comté, France

  • Institut Claudius Regaud, IUCT-Oncopole

    Toulouse, Haute-Garonne, France

  • Centre Hospitalier Universitaire (CHU) de Lille

    Lille, Hauts-de-France, France

  • Begin Army Instruction Hospital

    Saint-Mandé, Île-de-France Region, France

  • Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Institut Bergonie

    Bordeaux, New Aquitaine, France

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, New Aquitaine, France

  • Nantes University Hospital

    Nantes, Pays de la Loire Region, France

  • Centre Antoine Lacassagne

    Nice, Provence Alpes Cote dAzur, France

  • Soroka University Medical Center

    Beersheba, Israel

  • Rambam Health Care Campus

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Sheba Medical Center

    Ramat Gan, Central District, Israel

  • Netherlands Cancer Institute

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.